Bibliography
- Marsh S , MallonMA, GoodfellowP, McLeodHL: Concordance of pharmacogenetic markers in germline and colorectal tumor DNA.Pharmacogenomics6(8) , 873–877 (2005).
- Rae JM , CorderoKE, ScheysJO, LippmanME, FlockhartDA, JohnsonMD: Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.Pharmacogenetics13(8) , 501–507 (2003).
- Weiss JR , BaerMR, AmbrosoneCB et al.: Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia.Cancer Epidemiol. Biomarkers Prev.16(5) , 1038–1041 (2007).
- Schneider BP , RadovichM, SledgeGW et al.: Association of polymorphisms of angiogenesis genes with breast cancer.Breast Cancer Res. Treat.111(1) , 157–163 (2007).
- Xie B , FreudenheimJL, CummingsSS et al.: Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer.Carcinogenesis27(2) , 307–310 (2006).
- Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348(6) , 538–549 (2003).
- Deng G , LuY, ZlotnikovG, ThorAD, SmithHS: Loss of heterozygosity in normal tissue adjacent to breast carcinomas.Science274(5295) , 2057–2059 (1996).
- Tayeb MT , ClarkC, HaitesNE, SharpL, MurrayGI, McLeodHL: CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.Br. J. Cancer88(6) , 928–932 (2003).
- Sebolt-Leopold JS , EnglishJM: Mechanisms of drug inhibition of signalling molecules.Nature441(7092) , 457–462 (2006).
- Irmer D , FunkJO, BlaukatA: EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy.Oncogene26(39) , 5693–5701 (2007).
- Moutinho C , MateusAR, MilaneziF, CarneiroF, SerucaR, SurianoG: Epidermal growth factor receptor structural alterations in gastric cancer.BMC Cancer8 , 10 (2008).
- Ikediobi ON : Somatic pharmacogenomics in cancer.Pharmacogenomics J.8(5) , 305–314 (2008).
- Gorre ME , MohammedM, EllwoodK et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science293(5531) , 876–880 (2001).
- Rapley EA , HockleyS, WarrenW et al.: Somatic mutations of KIT in familial testicular germ cell tumours.Br. J. Cancer90(12) , 2397–2401 (2004).
- Demetri GD : Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).Eur. J. Cancer38(Suppl. 5) , S52–S59 (2002).
- Marsh S , McKayJA, CassidyJ, McLeodHL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.Int. J. Oncol.19(2) , 383–386 (2001).